Structure-activity relationships of pyrroloquinazolines as thrombin receptor antagonists

Bioorganic and Medicinal Chemistry Letters

Volumn 9, Issue 14, 1999, Pages 2073-2078

  Ahn, Ho Sam ^a   Arik, Leyla ^a   Boykow, George ^a   Burnett, Duane A ^a   Caplen, Mary Ann ^a   Czarniecki, Michael ^a   Domalski, Martin S ^a   Foster, Carolyn ^a   Manna, Mahua ^a   Stamford, Andrew W ^a   Wu, Yusheng ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PYRROLE DERIVATIVE; QUINAZOLINE DERIVATIVE; RECEPTOR BLOCKING AGENT; THROMBIN RECEPTOR; THROMBIN RECEPTOR ACTIVATING PEPTIDE;

ARTICLE; DERIVATIZATION; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG SCREENING; DRUG SYNTHESIS; RECEPTOR AFFINITY; STRUCTURE ACTIVITY RELATION; THROMBOCYTE AGGREGATION INHIBITION;

DRUG EVALUATION, PRECLINICAL; HUMANS; INHIBITORY CONCENTRATION 50; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PYRROLES; QUINAZOLINES; RECEPTOR, PAR-1; RECEPTORS, THROMBIN; STRUCTURE-ACTIVITY RELATIONSHIP; THROMBIN;

EID: 0033584185     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(99)00339-X     Document Type: Article

References (17)

1. Baykal, D.; Schmedtje, J. F.; Runge, M. S. Am. J. Cardiol. 1995, 75, 72B.
2. Vu, T. K. H.; Hung, D.; Wheaton, V. I.; Coughlin, S. R. Cell 1991, 64, 1057.
3. Rasmussen, U. B.; Vouret-Craviari, V.; Jallat, S.; Schlesinger, Y.; Pagés, G.; Pavirani, A.; Lecocq, J.-P.; Pouysségur, J.; Van Obberghen-Schiling, E. FEBS Lett. 1991, 288, 123.
4. Bernatowicz, M.S.; Klimas, C. E.; Hartl, K. S.; Peluso, M.; Allegretto, N. J.; Seiler, S. M. J. Med. Chem. 1996, 39, 4879.
5. Hoekstra, W. J.; Hulshizer, B. L.; McComsey, D. F.; Andrade-Gordon, P.; Kauffman, J. A.; Addo, M. F.; Oksenberg, D.; Scarborough, R. M.; Maryanoff, B. E. Bioorg. Med. Chem. Lett. 1998, 8, 1649.
6. A Fujisawa group has reported a small molecule inhibitor of the thrombin receptor: Kato, Y.; Kita, Y.; Nishio, M.; Ito, K. Yamanaka, T.; Seki, J. 70th Annual Meeting of the Japanese Pharmacological Society, Chiba, Japan, March 22-25, 1997.
7. Ledig, K. W. US Patent 4,118,561 (1978);
8. K. W. Ledig, US Patent 4,208,520 (1980).
9. Jones, M. L.; Kuyper, L. F.; Styles, V. L.; Caddell, J. M. J. Heterocyclic Chem. 1994, 31, 1681.
10. All products were washed with water and hexane. Product purities were assessed by TLC and LC/MS where possible. NMR confirmed the product structure on a sampling of reactions. The analogs thus prepared were >90% pure. The most active analogs were resynthesized and purified for confirmation.
11. Feng, D.-M.; Veber, D. F.; Connolly, T. M.; Condra, C.; Tang, M.-J.; Nutt, R. F. J. Med. Chem. 1995, 38, 4125.
12. The thrombin receptor binding assay was carried out by the published procedure. Ahn, H-S.; Foster, C.; Boykow, G.; Arik, L.; Smith-Torhan, A.; Hesk, D.; Chatterjee, M. Mol. Pharm. 1997, 51, 350.
13. 3 resulted in concomitant displacement of the substituent at C1.
14. 5: C, 74.36; H, 6.78; N, 18.85%. Found: C, 74.53; H, 7.08; N, 18.44%.
15. The platelet aggregation assay was carried out by the published procedure. Bednar, B.; Condra, C.; Gould, R. J.; Connolly, R. M. Thrombosis Res. 1995, 77, 453.
16. Kahn, M. L.; Nakanishi-Matsui, M.; Shapiro, M. J.; Ishihara, H.; Coughlin, S. J. Clin. Invest. 1999, 103, 879-887.
17. Xu, W.-F.; Anderson, H.; Whitmore, T. E.; Presnell, S. R.; Yee, D. P.; Ching, A.; Gilbert, T.; Davie, E. W.; Foster, D. C. Proc. Nat Acad. Sci. USA 1998, 95, 6642-6646.